HomeCompareSFDYX vs ABBV

SFDYX vs ABBV: Dividend Comparison 2026

SFDYX yields 21.91% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $21.7K in total portfolio value· pulled ahead in Year 9
10 years
SFDYX
SFDYX
● Live price
21.91%
Share price
$27.84
Annual div
$6.10
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$82.1K
Annual income
$8,225.32
Full SFDYX calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — SFDYX vs ABBV

📍 ABBV pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSFDYXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SFDYX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SFDYX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SFDYX
Annual income on $10K today (after 15% tax)
$1,862.70/yr
After 10yr DRIP, annual income (after tax)
$6,991.52/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, ABBV beats the other by $14,534.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SFDYX + ABBV for your $10,000?

SFDYX: 50%ABBV: 50%
100% ABBV50/50100% SFDYX
Portfolio after 10yr
$92.9K
Annual income
$16,775.05/yr
Blended yield
18.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SFDYX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SFDYX buys
0
ABBV buys
0
No recent congressional trades found for SFDYX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSFDYXABBV
Forward yield21.91%3.09%
Annual dividend / share$6.10$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$82.1K$103.7K
Annual income after 10y$8,225.32$25,324.79
Total dividends collected$48.8K$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SFDYX vs ABBV ($10,000, DRIP)

YearSFDYX PortfolioSFDYX Income/yrABBV PortfolioABBV Income/yrGap
1$12,891$2,191.42$11,555$434.96+$1.3KSFDYX
2$16,434$2,640.23$13,485$635.47+$2.9KSFDYX
3$20,730$3,145.59$15,933$937.67+$4.8KSFDYX
4$25,889$3,708.28$19,118$1,400.80+$6.8KSFDYX
5$32,030$4,328.24$23,384$2,125.24+$8.6KSFDYX
6$39,276$5,004.51$29,290$3,286.81+$10.0KSFDYX
7$47,761$5,735.28$37,776$5,205.38+$10.0KSFDYX
8$57,622$6,517.98$50,495$8,488.44+$7.1KSFDYX
9← crossover$69,005$7,349.30$70,497$14,346.44$1.5KABBV
10$82,061$8,225.32$103,718$25,324.79$21.7KABBV

SFDYX vs ABBV: Complete Analysis 2026

SFDYXStock

Under normal circumstances, the fund will invest at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in equity securities of medium-sized companies. In managing the fund's assets, the Sub-Advisers select stocks of companies that have low price-earnings and price-book ratios, but that also have high sustainable growth levels and the probability of high positive earnings revisions.

Full SFDYX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SFDYX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SFDYX vs SCHDSFDYX vs JEPISFDYX vs OSFDYX vs KOSFDYX vs MAINSFDYX vs JNJSFDYX vs MRKSFDYX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.